Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.48 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | DUT | P33316 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13672356 | 1.00 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3CYP3A4 | |
| SCHEMBL18281054 | 1.00 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3CYP3A4 | |
| SCHEMBL15062555 | 1.00 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3CYP3A4 | |
| SCHEMBL16742443 | 1.00 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3CYP3A4 | |
| SCHEMBL768095 | 1.00 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3CYP3A4 | |
| SCHEMBL24371645 | 1.00 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3CYP3A4 | |
| SCHEMBL21418798 | 1.00 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3CYP3A4 | |
| SCHEMBL20912764 | 1.00 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3CYP3A4 | |
| SCHEMBL21143517 | 1.00 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3CYP3A4 | |
| SCHEMBL12194656 | 1.00 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | claimed |
| EP-3303362-B1 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2022-10-19 | — | — | EP | claimed |
| US-10239910-B2 | Process for the preparation of sofosbuvir | OPTIMUS DRUGS (P) LIMITED (IN) | 2019-03-26 | — | — | US | claimed |
| US-10000522-B2 | Derivatives of uridine 5′-cyclophosphate useful to treat hepatitis C viral infections | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2018-06-19 | — | — | US | claimed |
| US-20170334942-A1 | DERIVATIVES OF URIDINE 5'-CYCLOPHOSPHATE USEFUL TO TREAT HEPATITIS C VIRAL INFECTIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-11-23 | — | — | US | claimed |
| WO-2017093973-A1 | PROCESS FOR THE PREPARATION OF PURE SOFOSBUVIR | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-08 | — | — | WO | claimed |
| EP-2432792-B1 | AND PROCESS FOR THE PREPARATION OF N-[(2'R)-2'-DEOXY-2'-FLUORO-2'-METHYL-P-PHENYL-5'-URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER | GILEAD PHARMASSET LLC (US) | 2016-07-06 | — | — | EP | claimed |
| US-20140121366-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2014-05-01 | — | — | US | claimed |
| US-8642756-B2 | Nucleoside phosphoramidates | GILEAD PHARMASSET LLC (US) | 2014-02-04 | — | — | US | claimed |
| EP-2609923-A2 | Nucleoside Phosphoramidates | Gilead Pharmasset LLC (US) | 2013-07-03 | — | — | EP | claimed |
| EP-2552930-A2 | NUCLEOSIDE PHOSPHORAMIDATES | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | claimed |
| EP-2432792-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | Pharmasset, Inc. (US) | 2012-03-28 | — | — | EP | claimed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | claimed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| WO-2010135569-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | PHARMASSET, INC. (US) | 2010-11-25 | — | — | WO | claimed |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-11-25 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | UNIV EMORY (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2009073506-A2 | NUCLEOSIDE PRODRUGS AND USES THEREOF | METABASIS THERAPEUTICS INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008121634-A2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121366-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | SLC29A1 40/4885SLC28A1 67/4885SLC28A2 88/4885 |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | SLC29A1 36/4885SLC28A1 59/4885SLC28A2 84/4885 |
| US-10000522-B2 | Derivatives of uridine 5′-cyclophosphate useful to treat hepatitis C viral infections | UMPS, NUDT14, PNP | SLC29A1 108/4885SLC28A1 174/4885SLC28A2 165/4885 |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | SLC29A1 40/4885SLC28A1 67/4885SLC28A2 88/4885 |
| US-10239910-B2 | Process for the preparation of sofosbuvir | SAMHD1, CPSF1, APOBEC3G | SLC29A1 812/4885SLC28A1 776/4885SLC28A2 1012/4885 |
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | DCTD, RNMT, NSUN2 | SLC29A1 11/4885SLC28A1 12/4885SLC28A2 8/4885 |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | SLC29A1 36/4885SLC28A1 59/4885SLC28A2 84/4885 |
| US-20170334942-A1 | DERIVATIVES OF URIDINE 5'-CYCLOPHOSPHATE USEFUL TO TREAT HEPATITIS C VIRAL INFECTIONS | UMPS, NUDT14, PNP | SLC29A1 110/4885SLC28A1 181/4885SLC28A2 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.